Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
The purpose of this study is to test the safety of MEDI-570 at different doses to find out what effects, if any, it has on people. This drug has been tested in people for treatment of an autoimmune disease, given by subcutaneous (under the skin) injections. There will be about 4 to 46 people taking part in this study. Another purpose of this study is for researchers to learn if a biomarker test is helpful or not to decide if MEDI-570 has clinical activity in lymphomas that have the ICOS protein.
Primary Objectives: To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of MEDI-570 in patients with refractory/relapsed peripheral T-cell lymphoma (PTCL) follicular variant and angioimmunoblastic T-cell lymphoma (AITL).